| 1 |
32357825 | The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells. | 2020 |
1 |
| 2 |
29281902 | Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. | 2018 Feb |
1 |
| 3 |
28979810 | Enhancing chemotherapy sensitivity by targeting PcG via the ATM/p53 pathway. | 2017 |
2 |
| 4 |
25268149 | Epirubicin loading in poly(butyl cyanoacrylate) nanoparticles manifests via altered intracellular localization and cellular response in cervical carcinoma (HeLa) cells. | 2016 Sep |
3 |
| 5 |
25713207 | Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells. | 2015 May |
2 |
| 6 |
22815059 | A novel anti-DR5 chimeric antibody and epirubicin synergistically suppress tumor growth. | 2012 Sep |
1 |
| 7 |
21441950 | Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms. | 2011 Aug 18 |
1 |
| 8 |
21514041 | Gene expression signature of TP53 but not its mutation status predicts response to sequential paclitaxel and 5-FU/epirubicin/cyclophosphamide in human breast cancer. | 2011 Aug 28 |
1 |
| 9 |
21518729 | ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance. | 2011 Jun |
4 |
| 10 |
21556366 | Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. | 2011 Apr 27 |
4 |
| 11 |
21906442 | [Combination of AD5-10 and epirubicin in treating rheumatoid arthritis]. | 2011 Aug |
2 |
| 12 |
18511948 | NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. | 2008 Jul |
2 |
| 13 |
18606222 | Inhibit multidrug resistance and induce apoptosis by using glycocholic acid and epirubicin. | 2008 Sep 2 |
1 |
| 14 |
18725978 | CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. | 2008 Aug 26 |
1 |
| 15 |
17388661 | Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. | 2007 Mar |
2 |
| 16 |
17876337 | Changes in allelic imbalances in locally advanced breast cancers after chemotherapy. | 2007 Oct 22 |
1 |
| 17 |
11935300 | p53 Gene status in relation to ex vivo chemosensitivity of non-small cell lung cancer. | 2002 Mar |
1 |
| 18 |
10914720 | p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. | 2000 Jul |
7 |
| 19 |
9415415 | Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry. | 1997 Dec 1 |
1 |